BACKGROUND: Accumulation of amyloid beta (Abeta) in the brain is believed to represent one of the earliest events in the Alzheimer disease process. Abeta is generated from amyloid precursor protein after sequential cleavage by beta- and gamma-secretase. Alternatively, alpha-secretase cleaves within the Abeta sequence, thus, precluding the formation of Abeta. A lot of research has focused on Abeta production, while less is known about the non-amyloidogenic pathway. We have previously shown that Abeta is present in human cerebrospinal fluid (CSF) as several shorter C-terminal truncated isoforms (e.g. Abeta1-15 and Abeta1-16), and that the levels of these shorter isoforms are elevated in media from cells that have been treated with gamma-secretase inhibitors. OBJECTIVE: To explore the effect of N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), a gamma-secretase-inhibitor, treatment on the Abeta isoform pattern in brain tissue and CSF from Tg2576 mice. METHODS: Immunoprecipitation using the anti-Abeta antibodies 6E10 and 4G8 was combined with either matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or nanoflow liquid chromatography and tandem mass spectrometry. RESULTS: All fragments longer than and including Abeta1-17 displayed a tendency towards decreased levels upon gamma-secretase inhibition, whereas Abeta1-15 and Abeta1-16 indicated slightly elevated levels during treatment. CONCLUSION: These data suggest that Abeta1-15 and Abeta1-16 may be generated through a third metabolic pathway independent of gamma-secretase, and that these Abeta isoforms may serve as biomarkers for secretase inhibitor treatment. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: Accumulation of amyloid beta (Abeta) in the brain is believed to represent one of the earliest events in the Alzheimer disease process. Abeta is generated from amyloid precursor protein after sequential cleavage by beta- and gamma-secretase. Alternatively, alpha-secretase cleaves within the Abeta sequence, thus, precluding the formation of Abeta. A lot of research has focused on Abeta production, while less is known about the non-amyloidogenic pathway. We have previously shown that Abeta is present in human cerebrospinal fluid (CSF) as several shorter C-terminal truncated isoforms (e.g. Abeta1-15 and Abeta1-16), and that the levels of these shorter isoforms are elevated in media from cells that have been treated with gamma-secretase inhibitors. OBJECTIVE: To explore the effect of N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), a gamma-secretase-inhibitor, treatment on the Abeta isoform pattern in brain tissue and CSF from Tg2576mice. METHODS: Immunoprecipitation using the anti-Abeta antibodies 6E10 and 4G8 was combined with either matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or nanoflow liquid chromatography and tandem mass spectrometry. RESULTS: All fragments longer than and including Abeta1-17 displayed a tendency towards decreased levels upon gamma-secretase inhibition, whereas Abeta1-15 and Abeta1-16 indicated slightly elevated levels during treatment. CONCLUSION: These data suggest that Abeta1-15 and Abeta1-16 may be generated through a third metabolic pathway independent of gamma-secretase, and that these Abeta isoforms may serve as biomarkers for secretase inhibitor treatment. Copyright 2009 S. Karger AG, Basel.
Authors: I Hussain; D Powell; D R Howlett; D G Tew; T D Meek; C Chapman; I S Gloger; K E Murphy; C D Southan; D M Ryan; T S Smith; D L Simmons; F S Walsh; C Dingwall; G Christie Journal: Mol Cell Neurosci Date: 1999-12 Impact factor: 4.314
Authors: R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney Journal: Nature Date: 1999-12-02 Impact factor: 49.962
Authors: S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John Journal: Nature Date: 1999-12-02 Impact factor: 49.962
Authors: Erik Portelius; Eric Price; Gunnar Brinkmalm; Mark Stiteler; Maria Olsson; Rita Persson; Ann Westman-Brinkmalm; Henrik Zetterberg; Adam J Simon; Kaj Blennow Journal: Neurobiol Aging Date: 2009-07-14 Impact factor: 4.673
Authors: John R Cirrito; Patrick C May; Mark A O'Dell; Jennie W Taylor; Maia Parsadanian; Jeffrey W Cramer; James E Audia; Jeffrey S Nissen; Kelly R Bales; Steven M Paul; Ronald B DeMattos; David M Holtzman Journal: J Neurosci Date: 2003-10-01 Impact factor: 6.167
Authors: Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer Journal: J Biol Chem Date: 2012-01-20 Impact factor: 5.157
Authors: Erik Portelius; Nenad Bogdanovic; Mikael K Gustavsson; Inga Volkmann; Gunnar Brinkmalm; Henrik Zetterberg; Bengt Winblad; Kaj Blennow Journal: Acta Neuropathol Date: 2010-04-24 Impact factor: 17.088
Authors: Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow Journal: Neuromolecular Med Date: 2012-12-07 Impact factor: 3.843
Authors: Erik Portelius; Robert A Dean; Mikael K Gustavsson; Ulf Andreasson; Henrik Zetterberg; Eric Siemers; Kaj Blennow Journal: Alzheimers Res Ther Date: 2010-03-29 Impact factor: 6.982
Authors: Erik Portelius; Juan Fortea; Jose Luis Molinuevo; Mikael K Gustavsson; Ulf Andreasson; Raquel Sanchez-Valle Journal: Mol Med Rep Date: 2012-02-01 Impact factor: 2.952
Authors: Roberta Ghidoni; Anna Paterlini; Valentina Albertini; Elena Stoppani; Giuliano Binetti; Kjell Fuxe; Luisa Benussi; Luigi F Agnati Journal: J Biomed Biotechnol Date: 2011-08-23
Authors: Diana W Shineman; Guriqbal S Basi; Jennifer L Bizon; Carol A Colton; Barry D Greenberg; Beth A Hollister; John Lincecum; Gabrielle G Leblanc; Linda Bobbi H Lee; Feng Luo; Dave Morgan; Iva Morse; Lorenzo M Refolo; David R Riddell; Kimberly Scearce-Levie; Patrick Sweeney; Juha Yrjänheikki; Howard M Fillit Journal: Alzheimers Res Ther Date: 2011-09-28 Impact factor: 6.982
Authors: Niklas Mattsson; Lawrence Rajendran; Henrik Zetterberg; Mikael Gustavsson; Ulf Andreasson; Maria Olsson; Gunnar Brinkmalm; Johan Lundkvist; Laura H Jacobson; Ludovic Perrot; Ulf Neumann; Herman Borghys; Marc Mercken; Deborah Dhuyvetter; Fredrik Jeppsson; Kaj Blennow; Erik Portelius Journal: PLoS One Date: 2012-02-06 Impact factor: 3.240